Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Research dashboard

Search approved medicines for AI-predicted activity against four drug-resistant pathogens, and see what evidence is already documented for each one.

TryTuberculosisMRSAKlebsiella infectionE. coli infection

1,761

Approved medicines

Approved medicines matched to the FDA Orange Book, antimicrobials included

1,276

Medicines with ≥40% AI-predicted activity

Against at least one of the four supported pathogens; each medicine counted once

1,019

Repurposing candidates

Of those, the medicines that are not already antimicrobials

How the repurposing candidates are counted

  1. 1,761approved medicines

  2. 1,276with AI-predicted activity ≥40% against at least one pathogen

    − 485 below ≥40%, not counted

  3. 1,120not already antimicrobials

    − 156 already antimicrobials, set aside

  4. 1,019repurposing candidates

    − 101 needing review, kept in the library

Existing antimicrobials are identified from WHO ATC codes and FDA pharmacologic classes. Medicines needing review (neither source says whether they are antimicrobials) stay in the approved-medicine download, marked “unclassified”. They are not assumed to be non-antimicrobials, so they are not counted as candidates.

Downloads

Download approved medicines (CSV)1,761 rowsDownload repurposing candidates (CSV)1,019 rows

Pathogen coverage

A medicine can count under more than one

Registered studies

A registration describes a study; it does not establish a positive result.

Condition
When these studies started38,873 of 39,548 have a start date · most in 2021 (1,903)
193119812030

  • 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

    NCT06991738 · start 2026-10-04

    Registered record
    Registry ID
    NCT06991738
    Conditions
    Thyroid Cancer
    Interventions
    68Ga-DOTA-TATE PET Scan; Amino acid infusions; 177Lu-DOTA-EB-TATE
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-04
    Completion
    2032-08-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Cancer
    Intervention68Ga-DOTA-TATE PET Scan; Amino acid infusions; 177Lu-DOTA-EB-TATE
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

    NCT07169630 · start 2026-10-04

    Registered record
    Registry ID
    NCT07169630
    Conditions
    Alzheimer s Disease; Mild Cognitive Impairment; Healthy
    Interventions
    18F-PF974; 18F-florbetaben
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-10-04
    Completion
    2030-04-11
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer s Disease; Mild Cognitive Impairment; Healthy
    Intervention18F-PF974; 18F-florbetaben
    PhasePhase 1
    Registry statusRecruiting

  • Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia

    NCT07495943 · start 2026-10-04

    Registered record
    Registry ID
    NCT07495943
    Conditions
    Fibromyalgia Syndrome; Fibromyalgia
    Interventions
    2-Aticyto Complex and D-ribose Oral Supplement; Placebo syrup
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-10-04
    Completion
    2027-05-04
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibromyalgia Syndrome; Fibromyalgia
    Intervention2-Aticyto Complex and D-ribose Oral Supplement; Placebo syrup
    PhaseNot applicable
    Registry statusNot yet recruiting

  • IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

    NCT07686380 · start 2026-10-04

    Registered record
    Registry ID
    NCT07686380
    Conditions
    Recurrent Prostate Cancer; Prostate Cancer
    Interventions
    N-803; ETBX-71 Vaccine; 18F-DCFPyL
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-10-04
    Completion
    2029-01-30
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Prostate Cancer; Prostate Cancer
    InterventionN-803; ETBX-71 Vaccine; 18F-DCFPyL
    PhasePhase 2
    Registry statusRecruiting

  • CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

    NCT07257419 · start 2026-10-03

    Registered record
    Registry ID
    NCT07257419
    Conditions
    Relapsed Pediatric ALL; Hematopoietic Cell Transplantation; Hematologic Malignancy
    Interventions
    Anti-Thymocyte Globulin (Rabbit); Cyclophosphamide; Fludarabine; Thiotepa; Mesna; Melphalan; Filgrastim; CliniMACS System
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-10-03
    Completion
    2035-12
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Pediatric ALL; Hematopoietic Cell Transplantation; Hematologic Malignancy
    InterventionAnti-Thymocyte Globulin (Rabbit); Cyclophosphamide; Fludarabine; Thiotepa +4 more
    PhasePhase 1
    Registry statusRecruiting

  • A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

    NCT07285798 · start 2026-10-02

    Registered record
    Registry ID
    NCT07285798
    Conditions
    Irritability Associated With Autism Spectrum Disorder
    Interventions
    KarXT; KarX-EC; KarXT + KarX-EC Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-02
    Completion
    2029-08-06
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritability Associated With Autism Spectrum Disorder
    InterventionKarXT; KarX-EC; KarXT + KarX-EC Matching Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction

    NCT04383262 · start 2026-10-01

    Registered record
    Registry ID
    NCT04383262
    Conditions
    Laryngopharyngeal Reflux
    Interventions
    Fosamprenavir Calcium; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-10-01
    Completion
    2028-10-01
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLaryngopharyngeal Reflux
    InterventionFosamprenavir Calcium; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Multimodal Imaging Study of Dopamine in Early Psychosis

    NCT06977308 · start 2026-10-01

    Registered record
    Registry ID
    NCT06977308
    Conditions
    Clinical High Risk for Psychosis (CHR)
    Interventions
    Methylphenidate (MPH); [11C]raclopride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2030-10-01
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical High Risk for Psychosis (CHR)
    InterventionMethylphenidate (MPH); [11C]raclopride
    PhasePhase 1
    Registry statusNot yet recruiting

  • Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

    NCT06982222 · start 2026-10-01

    Registered record
    Registry ID
    NCT06982222
    Conditions
    Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Prostate Adenocarcinoma; Stage IV Lung Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Biospecimen Collection; Bone Scan; Computed Tomography; Positron Emission Tomography; PSMA PET Scan; Single Photon Emission Computed Tomography; Technetium TC-99m; Tin Sn 117m Pentetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2026-10-01
    Completion
    2027-02-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone +3 more
    InterventionBiospecimen Collection; Bone Scan; Computed Tomography; Positron Emission Tomography +4 more
    PhasePhase 1
    Registry statusWithdrawn

  • Vascular Effects of SGLT2i in Non-diabetic CKD

    NCT07060417 · start 2026-10-01

    Registered record
    Registry ID
    NCT07060417
    Conditions
    Non-diabetic Chronic Kidney Disease
    Interventions
    Empagliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-09-30
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-diabetic Chronic Kidney Disease
    InterventionEmpagliflozin; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

    NCT07174349 · start 2026-10-01

    Registered record
    Registry ID
    NCT07174349
    Conditions
    Urinary Retention Postoperative
    Interventions
    Uroselective alpha-1-adrenergic receptor antagonist; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-10-01
    Completion
    2028-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Retention Postoperative
    InterventionUroselective alpha-1-adrenergic receptor antagonist; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)

    NCT07261150 · start 2026-10-01

    Registered record
    Registry ID
    NCT07261150
    Conditions
    Histoplasmosis
    Interventions
    LAmB B; Posaconazole; World Health Organization (WHO)-recommended SOC; WHO-recommended SOC Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2030-12-31
    Enrolment
    664

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHistoplasmosis
    InterventionLAmB B; Posaconazole; World Health Organization (WHO)-recommended SOC; WHO-recommended SOC Itraconazole
    PhasePhase 3
    Registry statusNot yet recruiting

  • Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

    NCT07293403 · start 2026-10-01

    Registered record
    Registry ID
    NCT07293403
    Conditions
    Follicular Helper T-Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Duvelisib; Positron Emission Tomography; Survey Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-10-01
    Completion
    2027-11-23
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Helper T-Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +3 more
    PhasePhase 2
    Registry statusRecruiting

  • An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service

    NCT07296770 · start 2026-10-01

    Registered record
    Registry ID
    NCT07296770
    Conditions
    Postsurgical Pain Management; Postsurgical Pain, Chronic; Opioid Use After Surgery
    Interventions
    TPS-Select; Pharmacologic Pain Management; Interventional Pain Procedures; Psychological Management and Pain Education; Physical Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2028-07-01
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostsurgical Pain Management; Postsurgical Pain, Chronic; Opioid Use After Surgery
    InterventionTPS-Select; Pharmacologic Pain Management; Interventional Pain Procedures; Psychological Management and Pain Education +1 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Efficacy and Safety of Aspirin and Lansoprazole for Prevention of Preterm Birth in High-Risk Pregnant Women: A Biomarker-Enriched Trial

    NCT07337655 · start 2026-10-01

    Registered record
    Registry ID
    NCT07337655
    Conditions
    Pre-term Birth
    Interventions
    Low-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2032-09-30
    Enrolment
    670

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-term Birth
    InterventionLow-Dose Aspirin Dose: 81 mg & Lansoprazole Dose: 30 mg; Standard of Care
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

AI-predicted activity is a model’s estimate that a molecule is active against a pathogen in the laboratory. It is not clinical effectiveness. The models describe each pathogen species; the data behind them rarely records resistant strains.